Randy Rich, MD

Articles by Randy Rich, MD

Rationale and Dose-Finding Studies of the Combination of Irinotecan and a Taxane on a Weekly Schedule

ByJohn R. Murren, MD,Kathleen Blum, RN,Randy Rich, MD

January 1st 2001

Cisplatin (Platinol)-based chemotherapy has been the standard systemic therapy for both non-small-cell and small-cell lung cancer for the past 2 decades, though the efficacy and benefit remain modest. Recently, several novel

Latest Updated Articles

Rationale and Dose-Finding Studies of the Combination of Irinotecan and a Taxane on a Weekly Schedule
January 1st 2001

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)